Key gaps No semaglutide trial programme publicly reports validated vaginal symptom patient-reported outcomes (dryness scales, dyspareunia scores, pH/microbiome endpoints) in regulatory product information, limiting incidence estimation for vaginal endpoints
The patient should be apprised of the potential hazard to the embryo or fetus, and increased fetal monitoring might be warranted if exposure occurred
Similar to any medication, this skin-brightening injection may have side effects alongside its benefits
The decision becomes whether pharmaceutical-grade standards and established company reputation justify premium pricing
Committee materials list the California Life Sciences Association, the American Diabetes Association and the Partnership for Safe Medicines among its supporters, as described in the Assembly Committee analysis
If they prescribe both at the same time, its important to closely follow their instructions and medical advice